Momenta Pharmaceuticals (NASDAQ:MNTA) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15), Morningstar.com reports. The firm had revenue of $4.85 million for the quarter, compared to the consensus estimate of $15.63 million. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The business’s revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.46) earnings per share.
Shares of MNTA traded up $0.70 during mid-day trading on Tuesday, reaching $21.40. The company’s stock had a trading volume of 825,300 shares, compared to its average volume of 853,923. The firm has a market capitalization of $1.60 billion, a P/E ratio of -17.83 and a beta of 1.63. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $21.75.
Top Biotech Stocks To Watch For 2019: AGL Resources, Inc.(GAS)
Advisors' Opinion:- [By Stephan Byrd]
Gas (CURRENCY:GAS) traded 12.9% higher against the U.S. dollar during the 1-day period ending at 22:00 PM ET on July 2nd. Gas has a market cap of $117.83 million and approximately $5.75 million worth of Gas was traded on exchanges in the last day. One Gas token can now be bought for approximately $11.63 or 0.00175551 BTC on exchanges including Cobinhood, Koinex, DragonEX and Binance. Over the last week, Gas has traded 10.4% higher against the U.S. dollar.
- [By Max Byerly]
Gas (CURRENCY:GAS) traded down 0.2% against the U.S. dollar during the 1 day period ending at 21:00 PM E.T. on May 19th. Over the last seven days, Gas has traded 10.8% lower against the U.S. dollar. Gas has a total market capitalization of $228.89 million and $5.00 million worth of Gas was traded on exchanges in the last day. One Gas token can currently be bought for $22.60 or 0.00274789 BTC on major exchanges including Abucoins, OKEx, Bitbns and Coinnest.
Top Biotech Stocks To Watch For 2019: Blackrock Health Sciences Trust(BME)
Advisors' Opinion:- [By Max Byerly]
B&M European Value Retail (LON:BME) had its target price boosted by analysts at HSBC from GBX 470 ($6.26) to GBX 500 ($6.66) in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective indicates a potential upside of 21.54% from the company’s current price.
- [By Logan Wallace]
Shares of BME traded up $0.60 during midday trading on Monday, hitting $40.92. The company had a trading volume of 34,700 shares, compared to its average volume of 35,130. Blackrock Health Sciences Trust has a 52 week low of $32.00 and a 52 week high of $44.00.
TRADEMARK VIOLATION WARNING: “Blackrock Health Sciences Trust Declares Monthly Dividend of $0.20 (BME)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4125742/blackrock-health-sciences-trust-declares-monthly-dividend-of-0-20-bme.html.About Blackrock Health Sciences Trust
- [By Logan Wallace]
Shares of B&M European Value Retail SA (LON:BME) have been assigned an average recommendation of “Buy” from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 451.36 ($5.88).
- [By Stephan Byrd]
Shares of B&M European Value Retail SA (LON:BME) have earned an average recommendation of “Buy” from the sixteen ratings firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 442.92 ($5.90).
Top Biotech Stocks To Watch For 2019: Tortoise MLP Fund, Inc.(NTG)
Advisors' Opinion:- [By Shane Hupp]
Shares of Northgate plc (LON:NTG) have received an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is GBX 523.25 ($6.67).
No comments:
Post a Comment